Sign in
Not yet taking people in SwedenPhase 3

Rituximab for Fibromyalgia Pain Linked to Autoantibodies

Tests rituximab for daily pain in adults with fibromyalgia.

Key facts

Who runs it
Region Stockholm – SLSO
Where
Lund, Malmö, and Stockholm, SwedenSee the 3 sites
Registry title
Rituximab as therapy for autoantibody mediated fibromyalgia (RAFT) - proof of concept
Status
Not yet recruiting
Phase
Phase 3
People taking part
15 people, planned
Started
1 Feb 2026
Expected to end
1 Feb 2027
Type of study
Interventional
Record updated
12 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with fibromyalgia and fibromyalgia-linked antibodies in the blood. It tests whether rituximab reduces daily pain.

Age
18–65 years in the criteria (the record lists 18 to 64 Years as the age limits).
Sex
All sexes can join.
Disease stage
Fibromyalgia diagnosed by a pain specialist or rheumatologist using the 1990 and 2016 criteria. Diagnosis no more than 2 years ago, symptoms started no more than 5 years ago. Pain score (VAS) of at least 50 mm on a 0-100mm scale.
Earlier treatment
Pain medicines unchanged for the 6 weeks before screening. At least three doses of a COVID-19 vaccine, or measurable COVID-19 antibodies. No rituximab before. No immunosuppressive treatment now or in the last 6 months. No opioids or benzodiazepines.
Biomarker or test result
Positive test for fibromyalgia-associated antibodies (Camilla Svensson's laboratory, Karolinska Institutet).

Main reasons for not taking part

  • Another autoimmune disease, except stable treated low thyroid function
  • Severe heart failure (NYHA Class IV) or severe uncontrolled heart disease
  • BMI over 35, or a neuropsychiatric diagnosis
  • Cancer within the past 5 years, known immune weakness, or ongoing infection such as HIV, latent tuberculosis, hepatitis B or C
  • Pregnancy, planned pregnancy or breastfeeding

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • The study participant must have provided written informed consent
  • The study participants must have been vaccinated with at least three doses of a COVID-19 vaccine or have measurable titers of anti-COVID-19 antibodies
  • Age 18–65 years
  • Patients with a diagnosis of fibromyalgia (FM) who meet the diagnostic criteria for FM and have been diagnosed by a treating pain specialist or rheumatologist trained in the use of these criteria (AAPT core diagnostic criteria 1990 and revised criteria from 2016)
  • FM disease duration since diagnosis no more than 2 years, and since symptom onset no more than 5 years
  • FM disease burden with VAS pain ≥ 50 mm (0-100mm)
  • The patient has tested positive for FM-associated antibodies (Camilla Svensson’s laboratory, Biomedicum, Karolinska Institutet) (2,3), according to current reference intervals
  • Pain treatment must have been stable without any change in medication or dosage during the 6 weeks prior to screening. For permitted substances, please see section 7.9
  • Women of childbearing potential must have a negative pregnancy test and use effective contraceptive methods throughout the entire study participation period, from baseline and for one year thereafter
  • The study participants must be able and willing to comply with all study procedures

Who cannot take part

  • Participation in any other clinical trial of an investigational drug, or exposure to any investigational product or procedure within 6 months prior to screening
  • Vaccination less than 4 weeks prior to inclusion
  • Previous use of rituximab for any indication
  • Any ongoing acute or chronic systemic infection, including HIV, latent tuberculosis, hepatitis B or C, or any other infection considered clinically significant by the study physician and not treated with appropriate antimicrobial therapy
  • Diagnosis of another autoimmune disease, exclusive stable, substituted hypothyreosis
  • Severe heart failure (New York Heart Association Class IV) or severe uncontrolled heart disease
  • Hypersensitivity to the active substance, murine proteins, or any other substance in the investigational medicinal product
  • Any medical condition that, in the judgment of the study physician, may interfere with the patient’s participation in the study, pose additional risk to the patient, or complicate the assessment of the patient
  • Any other disease, medical condition, or planned procedure that, in the opinion of the study physician, constitutes a contraindication for participation
  • Active malignancy within the past 5 years
  • Severe infection within the past 3 months
  • BMI > 35
  • Ongoing or recently discontinued (within the last 6 months) immunosuppressive treatment
  • Known immunodeficiency
  • Neuropsychiatric diagnosis
  • Use of opioids or benzodiazepine
  • Ongoing or planned pregnancy or breastfeeding

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 64 years old?

Where in Sweden

  • Lund University HospitalLund, SwedenNot yet recruiting
  • Skånes universitetssjukhus MalmöMalmö, SwedenNot yet recruiting
  • Region Stockholm – SLSOStockholm, SwedenNot yet recruiting

About the trial

What the trial wants to find out

To investigate whether Rx treatment can reduce the average daily pain measured with VAS during week 16 after given treatment with Rx.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Rituximab as therapy for autoantibody mediated fibromyalgia (RAFT) - proof of concept
Plain-language title
Rituximab for Fibromyalgia Pain Linked to AutoantibodiesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Criteria questions
Built from 2025-523465-21-00, who can take part
Record updated
12 February 2026